Keros Therapeutics Inc. (KROS)
NASDAQ · Healthcare
Keros Therapeutics Inc. annual/quarterly shareholder equity history from 2019 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Keros Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 303.1M, a 46.96% decrease year-over-year.
- Keros Therapeutics Inc. shareholder equity for 2025 were 303.1M, a 46.96% decrease from 2024.
- Keros Therapeutics Inc. shareholder equity for 2024 were 571.6M, a 72.04% increase from 2023.
- Keros Therapeutics Inc. shareholder equity for 2023 were 332.2M, a 19.75% increase from 2022.
- Keros Therapeutics Inc. shareholder equity for 2022 were 277.4M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Keros Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $303 |
| 2024 | $572 |
| 2023 | $332 |
| 2022 | $277 |
| 2021 | $243 |
| 2020 | $262 |
| 2019 | $-19 |
| Keros Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $303 |
| 2024-12-31 | $572 |
| 2023-12-31 | $332 |
| 2022-12-31 | $277 |
| 2021-12-31 | $243 |
| 2020-12-31 | $262 |
| 2019-12-31 | $-19 |
Keros Therapeutics Inc. Shareholder Equity — FAQ
Keros Therapeutics Inc. (KROS) shareholder equity over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KROS's shareholder equity history?
The chart and table above show Keros Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.